Daniel Palmacci joins Lonza as President of the Cell & Gene Division and member of the Executive Committee Daniel will commence his tenure with Lonza Group on 1 November 2022, […]
Autor: Firma Lonza Group Ltd.
Lonza and Touchlight collaborate on end-to-end mRNA offering
Collaboration expands Lonza’s end-to-end offering for mRNA manufacturing with additional, differentiated source of DNA raw material, Touchlight’s doggybone DNA (dbDNATM) Touchlight provides synthetic DNA through a cell-free enzymatic process, […]
Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin
In H1 2022, Lonza delivers CHF 3 billion sales and 16.8%1 CER sales growth CHF 987 million CORE EBITDA resulted in a margin of 33.1% H1 2022 CAPEX reached 28.2% of […]
Maria Soler Nunez appointed as Head, Group Operations
. Lonza appoints Maria Soler Nunez as Head, Group Operations Maria joins Lonza from Novartis where she has led the quality organization since 2020 Maria will commence her tenure with […]
Grand Opening of Kodiak Sciences‘ Purpose-Built Bioconjugation Facility to Support Potential Commercial Manufacture of KSI-301, an Antibody Biopolymer Conjugate for Retinal Diseases
. Purpose-built bioconjugation facility in Lonza’s Ibex® Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak’s lead product candidate KSI-301 for high-prevalence retinal diseases The opening […]
Lonza Announces Results of the 2022 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
Shareholders re-elected all existing members of the Board of Directors who stood for re-election and elected Marion Helmes and Roger Nitsch as new members of the Board of Directors Albert […]
Lonza Publishes Invitation to the 2022 Annual General Meeting and 2021 Annual and Sustainability Reports
. Annual General Meeting to take place on 5 May 2022 at the company’s headquarters in Basel, Switzerland Albert M. Baehny proposed for re-election as Chairman of the Board of […]
Christian Seufert appointed as President of Capsules and Health Ingredients Division
. Lonza appoints Christian Seufert as President of the CHI Division and member of the Executive Committee Christian brings a unique level of experience and expertise from a 20-year career […]
Lonza erzielt ein starkes Ergebnis in 2021 mit 20% Umsatzwachstum (kWk)
Lonza erzielt einen Umsatz von CHF 5.4 Milliarden und einem Umsatzwachstum von 20% (kWk)1 CHF 1.7 Milliarden Kern-EBITDA resultieren in einer Marge von 30,8% 2021 erreichten die Investitionsausgaben 24% des […]
Lonza Delivers Strong 2021 performance with 20% CER Sales Growth
Lonza delivers CHF 5.4 billion sales and 20% CER1 sales growth CHF 1.7 billion CORE EBITDA resulted in a margin of 30.8% 2021 CAPEX reached 24% of sales, supporting long-term plan […]